Information about our clinical trials can be found via the freely public registries clinicaltrialregister.eu, clinicaltrials.gov or on this page Clinical trials synopses.

The allergy digital portal provides healthcare professionals with access to the latest information, medical education resources and personalised services on allergy immunotherapy, including easy access to product information, scientific literature and presentations, clinical data and much more.

The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

Over the last few decades allergy has increased in prevalence to become the most common chronic disease in modern societies. The causes for this sudden change are not entirely clear, although they seem to be linked to ‘modern lifestyle’.

It appears that allergy immunotherapy is the only treatment to treat the cause, induce immunological tolerance and to prompt disease modification. Disease modification implies long term effect, prevention of asthma in children with allergic rhinitis and prevention of new allergies.

In ALK we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people with allergies all over the world.

Previous award ceremonies and winners

2019: Kornel Golebski, University of Amsterdam, the Netherlands

2005: Omid Akbari, Harvard University, United States of America 

2004: Christopher Lynn Kepley, Commonwealth University of Virginia, United States of America 

2003: Erika Ganglberger, University of Vienna, Austria 

2002: Miriam Fleur Moffatt, University of Oxford, United Kingdom 

2001: Eckard Hamelmann, Humboldt-University of Berlin, Germany 

2000: Mark Larché, Imperial College, London, United Kingdom

In ALK, we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people – children, adolescents, and adults – living with allergies all over the world. The Henning Løwenstein Research Award is a biannual award given to a young scientist who has shown excellence within the field of allergy. The winner receives a monetary grant* (€20,000 in 2024) and a travel grant to attend the award ceremony at ALK in Hørsholm, Denmark.

There is currently no call for applications.

For more information, please see the criterion and evaluation of the 2025-applications below.

An international Scientific Board evaluates the applications. Board members in 2025:

• Prof. Stephen Durham, Chairman of the award, England
• Dr. Henning Løwenstein, Honorary of the award, Denmark
• Prof. Stephen Till, England
• Prof. Mark Larche, Canada
• Prof. Motohiro Ebisawa, Japan
• Prof. Natalija Novak, Germany
• Prof. Jing Li, China

2025: Janice A. Layhadi, Imperial College London, United Kingdom

2024: Kelly Bruton, Stanford University, United States of America 

2021: Julia Esser-von Bieren, Technical University, Munich, Germany

2015: Stefanie Eyerich, Technical University and Helmholtz Center, Munich, Germany 

2013: Bianca Schaub, Ludwig-Maximilian-University, Munich, Germany 

2011: Zoulfia Allakhverdi, University of Montreal, Canada, and Natalija Novak, University of Bonn, Germany 

2009: Stephen J. Till, Imperial College London, United Kingdom

2007: Barbara Bohle, Medical University of Vienna, Austria

* If the winner is from a country where local legislation or medicolegal regulation prevents the transfer of monetary awards from the pharmaceutical industry to healthcare professionals, and in the case that the selected winner is a healthcare professional, the award is substituted by a travel grant or an educational grant of corresponding value. The grant is managed by ALK A/S and specified payment can only be given in the form of tickets or refund of tickets for a scientific or educational purpose, which is in agreement with the medicolegal regulation in that country. Accepted purposes could be transportation to a scientific congress or educational event, registration fees, educational charges or accommodation. ALK will ensure that each purpose is in agreement with the regulation in that particular country.

Allergy+ — ALK’s corporate strategy towards 2028

With this direction for the future, we are aiming for more. More specifically, we are aspiring to help 5 million people living with allergy annually by 2030 – that is more than double the number we helped in 2023.

Allergy+ is shaped by our mission to help people living with allergy, and they are therefore at the very centre of our four strategic pillars: Focus, Innovate, Optimise and Cultivate. Our strategy aims to further strengthen ALK’s leadership in long-term allergy treatment, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. It builds on our promise of providing life-changing solutions to the millions of people with allergy.

CEO Peter Halling says: “ALK is a growth story, and through our Allergy+ strategy, we are scaling for impact. When we developed the strategy last year, we recognised how ambitious it is. I'm proud of the entire ALK organisation and of our achievements over the first year with the strategy, demonstrating that we can deiver results while adapting to and leading change in the field of allergy. We are definitely on the right path, and we are ready for the next steps.”